id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_ucr5v4gzqnhu5jr3qkqmfteeya	Tamara A. Sussman	Clinical Trials in Metastatic Uveal Melanoma: Current Status	2020	7	.pdf	application/pdf	4565	522	49	Clinical Trials in Metastatic Uveal Melanoma: Current Status standard of care therapy is available for patients with metastatic uveal melanoma. We conducted a search for active clinical trials available worldwide for metastatic uveal melanoma on November 26, 2019, clinical trials for metastatic uveal melanoma discussed in this review are summarized in Table 1. NCT02768766 Intermittent selumetinib for uveal melanoma recruiting I Columbia University Medical Center; Memorial Sloan in metastatic uveal melanoma patients who have not received prior MEK inhibitor therapy (NCT02768766), targets the mitogen-activated protein kinase (MAPK) pathway, regardless of tumor mutational status. randomized phase 2 trial compared selumetinib to chemotherapy in 101 metastatic uveal melanoma patients virus is a phase 1 study of VSV-IFNbetaTYRP1 in patients with metastatic uveal or cutaneous melanoma phase 1 clinical trial available for uveal melanoma patients with leptomeningeal disease involves the administration of intrathecal nivolumab with intravenous available for metastatic uveal melanoma, trials were largely limited to "recruiting" status.	./cache/work_ucr5v4gzqnhu5jr3qkqmfteeya.pdf	./txt/work_ucr5v4gzqnhu5jr3qkqmfteeya.txt